AACAP Endorses the Inclusion of Methylphenidate in the WHO Model Lists of Essential Medicines.

Authors :: Cortese S
Coghill D
Mattingly GW
Rohde LA
Thom RP
Wilens TE
Wong ICK
Faraone SV
Source :: Journal of the American Academy of Child and Adolescent Psychiatry [J Am Acad Child Adolesc Psychiatry] 2024 Jul; Vol. 63 (7), pp. 663-665. Date of Electronic Publication: 2024 Feb 28.
Publication Year :: 2024
Abstract: Despite decades of clinical use and a large body of evidence, the WHO continues to exclude methylphenidate for attention-deficit/hyperactivity disorder (ADHD) from its EML. <superscript>1</superscript>  The exclusion of methylphenidate has dire implications for millions of individuals with ADHD worldwide, especially those living in low and low-middle income countries (LMIC), where governmental decisions to make medicines available are contingent on EML listing.<br /> (Copyright © 2024 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.)

Subjects :: Humans
Drugs, Essential
Child
Methylphenidate therapeutic use
Methylphenidate pharmacology
Attention Deficit Disorder with Hyperactivity drug therapy
Central Nervous System Stimulants pharmacology
Central Nervous System Stimulants therapeutic use
World Health Organization

Language :: English
ISSN :: 1527-5418
Volume :: 63
Issue :: 7
Database :: MEDLINE
Journal :: Journal of the American Academy of Child and Adolescent Psychiatry
Publication Type :: Editorial & Opinion
Accession number :: 38428579
Full Text :: https://doi.org/10.1016/j.jaac.2024.02.008

Full Text Access

Tools